Anti-Müllerian Hormone and Embryo Aneuploidy

Clinica de la Mujer Medicina Reproductiva, Chile

Status: Completed

Conditions: Aneuploidy; Infertility

Treatments: Other: preimplantation genetic test for aneuploidies (PGT-a)

Study type: Observational

Funder types: Other

Identifiers

NCT05723016

AMH 2023

Details and patient eligibility

About

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels.

Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Enrollment: 300 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.

Exclusion criteria

• Data from oocyte donation cycles

Trial design

300 participants in 6 patient groups

AMH < 0.5 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)

AMH 0.5-0.99 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)

AMH 1.0-1.49 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)

AMH 1.5-1.99 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)

AMH 2.0-4.99 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)

AMH > 5.0 ng/ml

Treatment:

Other: preimplantation genetic test for aneuploidies (PGT-a)